Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.

ABSTRACT: Coronavirus disease 2019, caused by SARS-CoV-2, remains an on-going pandemic, partly due to the emergence of variant viruses that can "break-through" the protection of the current vaccines and neutralizing antibodies (nAbs), highlighting the needs for broadly nAbs and next-generation vaccines. We report an antibody that exhibits breadth and potency in binding the receptor-binding domain (RBD) of the virus spike glycoprotein across SARS coronaviruses. Initially, a lead antibody was computationally discovered and crystallographically validated that binds to a highly conserved surface of the RBD of wild-type SARS-CoV-2. Subsequently, through experimental affinity enhancement and computational affinity maturation, it was further developed to bind the RBD of all concerning SARS-CoV-2 variants,

SUBMITTER: Jeong BS 

PROVIDER: S-EPMC8765073 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature